Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells.

The type of interaction between tumor-associated antigens and specialized antigen-presenting cells such as dendritic cells (DCs) is critical for the type of immunity that will be generated. MUC1, a highly O-glycosylated mucin, is overexpressed and aberrantly glycosylated in several tumor histotypes. This results in the expression of tumor-associated glycoforms and in MUC1 carrying the tumor-specific glycan Tn (GalNAcalpha1-O-Ser/Thr). Glycopeptides corresponding to three tandem repeats of MUC1, enzymatically glycosylated with 9 or 15 mol of GalNAc, were shown to specifically bind and to be internalized by immature monocyte-derived DCs (iDCs). Binding required calcium and the GalNAc residue and was competed out by GalNAc polymer and Tn-MUC1 or Tn-MUC2 glycopeptides. The macrophage galactose-type C-type lectin (MGL) receptor expressed on iDCs was shown to be responsible for the binding. Confocal analysis and ELISA done on subcellular fractions of iDCs showed that the Tn-MUC1 glycopeptides colocalized with HLA class I and II compartments after internalization. Importantly, although Tn-MUC1 recombinant protein was bound and internalized by MGL, the glycoprotein entered the HLA class II compartment, but not the HLA class I pathway. These data indicate that MGL expressed on iDCs is an optimal receptor for the internalization of short GalNAcs carrying immunogens to be delivered into HLA class I and II compartments. Such glycopeptides therefore represent a new way of targeting the HLA class I and II pathways of DCs. These results have possible implications in designing cancer vaccines.

[1]  G. Meijer,et al.  The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma , 2007, Cancer Immunology, Immunotherapy.

[2]  Y. van Kooyk,et al.  Schistosoma mansoni soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic cell activation. , 2007, Molecular immunology.

[3]  T. Irimura,et al.  The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation. , 2007, Glycobiology.

[4]  V. Apostolopoulos,et al.  Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835] , 2006, Breast Cancer Research.

[5]  M. Hollingsworth,et al.  Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. , 2006, Glycobiology.

[6]  P. Bruggen,et al.  Processing and presentation of tumor antigens and vaccination strategies. , 2006 .

[7]  E. Vadai,et al.  O‐glycosylated versus non‐glycosylated MUC1‐derived peptides as potential targets for cytotoxic immunotherapy of carcinoma , 2006, Clinical and experimental immunology.

[8]  E. Jaffee,et al.  Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology , 2005, Molecular Cancer Therapeutics.

[9]  F. Hanisch,et al.  Human Tumor Antigen MUC1 Is Chemotactic for Immature Dendritic Cells and Elicits Maturation but Does Not Promote Th1 Type Immunity 1 , 2005, The Journal of Immunology.

[10]  G. Meijer,et al.  Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. , 2005, Cancer research.

[11]  M. Biffoni,et al.  Recombinant Tumor-Associated MUC1 Glycoprotein Impairs the Differentiation and Function of Dendritic Cells1 , 2005, The Journal of Immunology.

[12]  C. Bertozzi,et al.  Glycans in cancer and inflammation — potential for therapeutics and diagnostics , 2005, Nature Reviews Drug Discovery.

[13]  Ola Blixt,et al.  Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells. , 2005, International immunology.

[14]  D. Kahne,et al.  Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn , 2005, Cancer Immunology, Immunotherapy.

[15]  C. Figdor,et al.  How C‐type lectins detect pathogens , 2005, Cellular microbiology.

[16]  R. Day,et al.  Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer , 2005, Cancer Immunology, Immunotherapy.

[17]  O. Johnell,et al.  The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans , 2005, European journal of immunology.

[18]  H. Lyerly,et al.  Recent developments in therapeutic cancer vaccines , 2005, Nature Clinical Practice Oncology.

[19]  A. Banham,et al.  A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein , 2004, British Journal of Cancer.

[20]  T. Geijtenbeek,et al.  Self- and nonself-recognition by C-type lectins on dendritic cells. , 2004, Annual review of immunology.

[21]  S. Gendler,et al.  Designer Glycopeptides for Cytotoxic T Cell–based Elimination of Carcinomas , 2004, The Journal of experimental medicine.

[22]  J. Guillot,et al.  Modification des glycoconjugués au cours du processus de cancérisation : cas des carcinomes mammaires , 2004 .

[23]  F. Hanisch,et al.  O‐Linked glycans control glycoprotein processing by antigen‐presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells , 2003, European journal of immunology.

[24]  Alessandra Cambi,et al.  Dual function of C-type lectin-like receptors in the immune system. , 2003, Current opinion in cell biology.

[25]  M. Biffoni,et al.  Regulated expression of MUC1 epithelial antigen in erythropoiesis , 2003, British journal of haematology.

[26]  T. Irimura,et al.  Macrophage C-type lectin on bone marrow-derived immature dendritic cells is involved in the internalization of glycosylated antigens. , 2002, Glycobiology.

[27]  Peter Roepstorff,et al.  Functional Conservation of Subfamilies of Putative UDP-N-acetylgalactosamine:Polypeptide N-Acetylgalactosaminyltransferases inDrosophila, Caenorhabditis elegans, and Mammals , 2002, The Journal of Biological Chemistry.

[28]  K. Fujioka,et al.  The Macrophage C-type Lectin Specific for Galactose/N-Acetylgalactosamine Is an Endocytic Receptor Expressed on Monocyte-derived Immature Dendritic Cells* , 2002, The Journal of Biological Chemistry.

[29]  K. Fujioka,et al.  Human macrophage lectin specific for galactose/N-acetylgalactosamine is a marker for cells at an intermediate stage in their differentiation from monocytes into macrophages. , 2002, International immunology.

[30]  J. Taylor‐Papadimitriou,et al.  MUC1 and the Immunobiology of Cancer , 2002, Journal of mammary gland biology and neoplasia.

[31]  W. Bornmann,et al.  Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. , 2002, Vaccine.

[32]  J. Taylor‐Papadimitriou,et al.  O-Linked Glycosylation in the Mammary Gland: Changes that Occur During Malignancy , 2001, Journal of Mammary Gland Biology and Neoplasia.

[33]  C. Leclerc,et al.  Anti-Tumor Immunity Provided by a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri-Tn Glycotope1 , 2001, The Journal of Immunology.

[34]  F. Hanisch,et al.  O-Glycosylation of the Mucin Type , 2001, Biological chemistry.

[35]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.

[36]  Simon C Watkins,et al.  The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells1 , 2000, The Journal of Immunology.

[37]  V. Apostolopoulos,et al.  MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines , 2000, Cancer Immunology, Immunotherapy.

[38]  J. Burchell,et al.  Macrophage–tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter‐receptor for the macrophage‐restricted receptor, sialoadhesin , 1999, Immunology.

[39]  P. Ciborowski,et al.  Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. , 1999, Cellular immunology.

[40]  M. Hollingsworth,et al.  Cloning of a Human UDP-N-Acetyl-α-d-Galactosamine:PolypeptideN-Acetylgalactosaminyltransferase That Complements Other GalNAc-Transferases in Complete O-Glycosylation of the MUC1 Tandem Repeat* , 1998, The Journal of Biological Chemistry.

[41]  J. Taylor‐Papadimitriou,et al.  The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine , 1996, Cancer Immunology, Immunotherapy.

[42]  T. Irimura,et al.  Molecular cloning and expression of cDNA encoding human macrophage C-type lectin. Its unique carbohydrate binding specificity for Tn antigen. , 1996, Journal of immunology.

[43]  M. Gelb,et al.  A link between catalytic activity, IgE-independent mast cell activation, and allergenicity of bee venom phospholipase A2. , 1995, Journal of immunology.

[44]  R. Dwek,et al.  Recognition of carbohydrate by major histocompatibility complex class I- restricted, glycopeptide-specific cytotoxic T lymphocytes , 1994, The Journal of experimental medicine.

[45]  P. Andrews,et al.  Synthesis of large multideterminant peptide immunogens using a poly-proline beta-turn helix motif. , 1993, Peptide research.

[46]  N. Peat,et al.  Structure and biology of a carcinoma-associated mucin, MUC1. , 1991, The American review of respiratory disease.

[47]  D. Kingsley,et al.  Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal UDP-GalNAc 4-epimerase deficient mutant , 1986, Cell.

[48]  P. van der Bruggen,et al.  Processing and presentation of tumor antigens and vaccination strategies. , 2006, Current opinion in immunology.

[49]  A. Vlad,et al.  Glycoprotein tumor antigens for immunotherapy of breast cancer. , 2004, Breast disease.

[50]  F. Penault-Llorca,et al.  [Modification of glycoconjugates during the carcinogenesis: the case of mammary carcinomas]. , 2004, Bulletin du cancer.

[51]  P. Roepstorff,et al.  Development and characterization of an antibody directed to an α-N-acetyl-D-galactosamine glycosylated MUC2 peptide , 2004, Glycoconjugate Journal.

[52]  S. Hakomori,et al.  Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. , 2001, Advances in experimental medicine and biology.